Literature DB >> 21530822

Serum immunologic markers for monitoring allergen-specific immunotherapy.

Mohamed H Shamji1, Louisa K James, Stephen R Durham.   

Abstract

Allergen immunotherapy is an effective treatment option in patients with IgE-mediated allergy, particularly in those who do not respond to usual antiallergic drugs. Successful immunotherapy has been associated with the suppression of allergic inflammation in target organs and increases in allergen-specific IgG antibodies, particularly the IgG(4) subclass. To date there are no biomarkers that are predictive of the clinical response to immunotherapy. This article explores the possibility that functional assays based on the ability of IgG to compete with IgE and inhibit IgE-allergen complex formation may be surrogate or predictive of the clinical response to immunotherapy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21530822     DOI: 10.1016/j.iac.2011.03.005

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  10 in total

Review 1.  Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.

Authors:  Jasper H Kappen; Stephen R Durham; Hans In 't Veen; Mohamed H Shamji
Journal:  Ther Adv Respir Dis       Date:  2016-09-27       Impact factor: 4.031

2.  Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens.

Authors:  Brian P Vickery; Jing Lin; Michael Kulis; Zhiyan Fu; Pamela H Steele; Stacie M Jones; Amy M Scurlock; Gustavo Gimenez; Ludmilla Bardina; Hugh A Sampson; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2012-11-27       Impact factor: 10.793

3.  Changes of micro-RNAs in asymptomatic subjects sensitized to Japanese cedar pollen after prophylactic sublingual immunotherapy.

Authors:  Bo Hou; Mariko Murata; Ahmad Shah Said; Hiroshi Sakaida; Sawako Masuda; Taiki Takahashi; Zhe Zhang; Kazuhiko Takeuchi
Journal:  Allergy Rhinol (Providence)       Date:  2015-02-11

4.  A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol.

Authors:  L Klimek; J Uhlig; R Mösges; K Rettig; O Pfaar
Journal:  Allergy       Date:  2014-10-06       Impact factor: 13.146

5.  Induction of Bronchial Tolerance After 1 Cycle of Monophosphoryl-A-Adjuvanted Specific Immunotherapy in Children With Grass Pollen Allergies.

Authors:  Martin Rosewich; Katharina Girod; Stefan Zielen; Ralf Schubert; Johannes Schulze
Journal:  Allergy Asthma Immunol Res       Date:  2016-05       Impact factor: 5.764

6.  Amb a 1 isoforms: Unequal siblings with distinct immunological features.

Authors:  M Wolf; T E Twaroch; S Huber; M Reithofer; M Steiner; L Aglas; M Hauser; I Aloisi; C Asam; H Hofer; M A Parigiani; C Ebner; B Bohle; P Briza; A Neubauer; F Stolz; B Jahn-Schmid; M Wallner; F Ferreira
Journal:  Allergy       Date:  2017-06-14       Impact factor: 13.146

7.  Differential Plasma-cell evolution is linked with Dermatophagoides pteronyssinus immunotherapy response.

Authors:  Tahia D Fernández; Enrique Gómez; Inmaculada Doña; Paloma Campo; Carmen Rondon; Miguel Gonzalez; Francisca Gomez; Francisca Palomares; Maria Salas; Miguel Blanca; Cristobalina Mayorga; Maria J Torres
Journal:  Sci Rep       Date:  2015-09-29       Impact factor: 4.379

Review 8.  Monitoring Allergen Immunotherapy Effects by Microarray.

Authors:  Christian Lupinek; Eva Wollmann; Rudolf Valenta
Journal:  Curr Treat Options Allergy       Date:  2016-04-20

9.  Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial.

Authors:  Andrzej Bożek; Krzysztof Kołodziejczyk; Renata Kozłowska; Giorgio Walter Canonica
Journal:  Clin Transl Allergy       Date:  2017-12-01       Impact factor: 5.871

10.  Allergen Immunotherapy-Induced Immunoglobulin G4 Reduces Basophil Activation in House Dust Mite-Allergic Asthma Patients.

Authors:  Mulin Feng; Xiaohui Zeng; Qiujuan Su; Xu Shi; Mo Xian; Rundong Qin; Jing Li
Journal:  Front Cell Dev Biol       Date:  2020-02-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.